BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24927996)

  • 1. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
    Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
    Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
    Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
    Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.
    Zhao M; Ma J; Zhu HY; Zhang XH; Du ZY; Xu YJ; Yu XD
    Mol Cancer; 2011 Aug; 10():104. PubMed ID: 21871133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.
    Smith JR; Clarke PA; de Billy E; Workman P
    Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of celastrol to inhibit hsp90 and cdc37 interaction.
    Zhang T; Li Y; Yu Y; Zou P; Jiang Y; Sun D
    J Biol Chem; 2009 Dec; 284(51):35381-9. PubMed ID: 19858214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.
    Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
    BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
    Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
    Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.
    Gray PJ; Stevenson MA; Calderwood SK
    Cancer Res; 2007 Dec; 67(24):11942-50. PubMed ID: 18089825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Hsp90 inhibitor FW-04-806 suppresses Bcr/Abl-mediated growth of leukemia cells by inhibiting proliferation and inducing apoptosis].
    Kong Y; Huang W; Cao P; Chen L; Luo Y; She B; Xu J; Ye M
    Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):890-8. PubMed ID: 26887616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
    Kou X; Jiang X; Liu H; Wang X; Sun F; Han J; Fan J; Feng G; Lin Z; Jiang L; Yang Y
    Cancer Sci; 2018 Oct; 109(10):3272-3284. PubMed ID: 30039622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity.
    Cheng CJ; Liu KX; Zhang M; Shen FK; Ye LL; Wu WB; Hou XT; Hao EW; Hou YY; Bai G
    Acta Pharmacol Sin; 2022 Apr; 43(4):1046-1058. PubMed ID: 34326484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
    Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
    Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
    Mawatari T; Ninomiya I; Inokuchi M; Harada S; Hayashi H; Oyama K; Makino I; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
    Int J Oncol; 2015 Dec; 47(6):2073-81. PubMed ID: 26497673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer.
    Wang L; Zhang L; Li L; Jiang J; Zheng Z; Shang J; Wang C; Chen W; Bao Q; Xu X; Jiang Z; Zhang J; You Q
    Sci Adv; 2019 Sep; 5(9):eaax2277. PubMed ID: 31555737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
    Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
    Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
    Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM
    J Exp Med; 2012 Feb; 209(2):275-89. PubMed ID: 22271573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.
    Smith JR; de Billy E; Hobbs S; Powers M; Prodromou C; Pearl L; Clarke PA; Workman P
    Oncogene; 2015 Jan; 34(1):15-26. PubMed ID: 24292678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel celastrol-triazole derivatives with Hsp90-Cdc37 disruption to induce tumor cell apoptosis.
    Li N; Chen C; Zhu H; Shi Z; Sun J; Chen L
    Bioorg Chem; 2021 Jun; 111():104867. PubMed ID: 33845380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.